HFHS 16-01: Phase II Study of Pembrolizumab in Combination With BCG After Endoscopic Ablation for Patients With High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma Unfit or Unwilling to be Treated With Nephroureterectomy

January 09, 2017
https://clinicaltrials.gov/ct2/show/NCT03345134
Cancer - Bladder
Principal Investigator: James O Peabody, MD

Pembrolizumab

Superficial

Upper Urinary tract transitional

nephroureterectomy

BCG

Open